In summary, our study demonstrates that oral CA treatment attenuates glial inflammation, reduces glycoconjugate accumulation, decreases neuronal apoptosis, improves gait & locomotor activities, and increases survival in a mouse model of Sandhoff disease through PPARα. The gene discussed is PPARA; the disease is Sandhoff disease.